GENE ONLINE|News &
BIO CEO 2022: Trends and Opportunities in Biotechnology Investments
In the midst of the global pandemic, venture funding has continued to reach record-breaking levels. In light of this emerging trend in the investment in biotechnology, the 2022 BIO CEO & Investor Conference began with a panel discussion on the recent data on venture trends and therapeutic and platform areas of growth. Additional investors also provided their outlook of 2022, areas of concern with the public health landscape, and opportunities for the sector.
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
